Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 10/20 | 0.50 |
| ▸ | RARB | P10826 | 10/20 | 0.50 |
| ▸ | RARG | P13631 | 10/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365027 | 0.93 | RARA (0.52) | RARARARBRARGSLC22A12ALDH1A1 | |
| SCHEMBL12365281 | 0.86 | RARA (0.42) | RARARARBRARGALDH1A1MAP4K4 | |
| SCHEMBL12365280 | 0.84 | ALDH1A1 (0.49) | RARARARBRARGALDH1A1KDM4E | |
| SCHEMBL12366958 | 0.84 | HTR2B (0.40) | RARARARBRARGSLC22A12MAP4K4 | |
| SCHEMBL12389562 | 0.80 | XDH (0.42) | RARARARBRARGSLC22A12XDH | |
| SCHEMBL12365024 | 0.79 | RARA (0.43) | RARARARBRARGMAP4K4XDH | |
| SCHEMBL12365694 | 0.77 | RARB (0.39) | RARARARBRARGALDH1A1 | |
| SCHEMBL12365291 | 0.77 | RARA (0.47) | RARARARBRARGSLC22A12ALDH1A1 | |
| SCHEMBL12366685 | 0.77 | HTR2B (0.42) | RARARARBRARGMAP4K4 | |
| SCHEMBL12365082 | 0.77 | ESR2 (0.46) | RARARARBRARGALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2177505-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | RARA 3177/4885RARB 3149/4885RARG 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.